OAR Signs on to Drug Pricing Comments
posted: September 26, 2018
The OAR signed on to the Coalition of State Rheumatology’s (CSRO) comments submitted to the Department of Health and Human Services in response to the request for information included in its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. The request was made after the President issued his “Blueprint to Lower Drug Prices” in early May.
The comments focused on addressing the proposed changes to Medicare Part B, the impact of manufacturer rebates and pharmacy benefit managers, and the provisions related to biosimilars.
The Department of Health and Human Services (HHS) has been requesting meetings with drug manufacturers and pharmacy benefit managers to discuss changes to the system. It is expected that the Center for Medicare and Medicaid Innovation (CMMI) will release a rule in response to the feedback gathered from the RFI and meetings with stakeholders within the next couple of months.